Using morpholino technology, eMHC was knocked down during critical heart development phases -HH12, 14 and 16 in the chick. Immunohistological techniques showed that eMHC is present in the early developing heart and that upon knockdown during early stages of heart morphogenesis western analysis has demonstrated a reduction of 82% in eMHC protein was achieved.
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Phenotypic analysis showed that this reduction resulted in atrial septa developing abnormally and ventricles appeared to have dilated cardiomyopathy and disrupted trabeculae development.
Atrial, ventricular and septal cell proliferation rates were unaffected by the knockdown of eMHC and staining with phalloidin indicated that the actin cytoskeleton remained comparable to control hearts. Detailed electrophysiological data has shown severe anomalies in the ventricular electrical activity in the eMHC knockdown heart. These data suggest that eMHC is a candidate gene in humans for atrial septal defects and dilated cardiomyopathy and plays a role in the electrophysiological conduction system. 
